Neuroscience
42 articles
Replacing saruparib's carboxamide yields an oral, brain-penetrant PARP1-selective inhibitor
- Aimed at CNS malignancies, the program replaced the carboxamide of saruparib with a series of heterocycles, targeting PARP1 over PARP2 to limit haematological toxicity.
- Caco-2 efflux, rather than the usual MDR1-MDCK assay, was used as a progression filter to select compounds with good unbound brain exposure.
- The lead compound was orally bioavailable and caused tumour regression in xenografts at a low dose, with a projected low clinical dose.
Swapping the primary carboxamide is a bold move, since that group anchors the nicotinamide pocket, and the heterocycles evidently kept the binding. The more useful lesson is the filter: if Caco-2 efflux predicts unbound brain exposure better than MDR1-MDCK, plenty of CNS programs may be discarding good compounds.
Crystal structures show how CNS-oriented EGFR TKIs gain potency, not just brain exposure
- Several EGFR TKIs redesigned for blood-brain barrier penetration were studied by X-ray crystallography and potency assays.
- The BBB-enhancing groups engage varied regions of the EGFR kinase domains, and biochemical and cellular potency generally improved.
- Salt-bridge-forming moieties combined with certain halogen substitutions worked best, pointing to a 'two-for-one' design logic.
CNS exposure and potency are usually traded off against each other, so a crystallographic case that the same polar or basic handle can buy both is useful. The salt-bridge-plus-halogen pairing is a concrete design rule I could try on my own kinase series. It does not address efflux or unbound brain concentrations, which still decide whether it works in a patient.
Structural Insights into Brain-Penetrant EGFR Tyrosine Kinase Inhibitors with Enhanced Potency ↗
Oral TREM2 agonist VG-3927 reaches the clinic with preclinical and first-in-human data
- The paper reports preclinical and first-in-human evaluation of VG-3927 (SAR448851), an orally dosed small-molecule TREM2 agonist for Alzheimer's disease.
- Public reports describe good tolerability across ascending doses, central nervous system penetration, and a drop in the soluble TREM2 marker in cerebrospinal fluid.
- This summary rests on the article listing and secondary reports, not the full text.
Most TREM2 efforts are antibodies, so a brain-penetrant oral agonist that shifts a CSF pharmacodynamic marker is a notable modality shift. The open question is whether lower soluble TREM2 reflects real receptor activation, since a marker can move without microglial function changing. The first-in-human data show exposure and engagement, not efficacy.
Aminopyrimidine NaV1.7 probe inhibits resting and inactivated states almost equally
- An automated patch-clamp screening cascade, built to deprioritize classic local-anesthetic pore binders, yielded an aminopyrimidine hit that was optimized into compound 6.
- Compound 6 combined balanced resting- and inactivated-state potency, selectivity over NaV1.5 and a tetrodotoxin-like isoform profile that includes NaV1.1.
- SAR pointed to the aminopyrimidine core and a methylene-linked aniline as key determinants of this profile.
State dependence is a leading suspect for why NaV1.7 programs keep failing clinically, so a probe that blocks resting and inactivated states alike is a good way to test that hypothesis. NaV1.1 activity is a flag for seizure-related liability, and I'd want a binding-site assignment before reading too much into the profile.
A Nontoxin Aminopyrimidine Probe for Near State-Independent Na V 1.7 Inhibition ↗
Turning EGFR kinase inhibitors into BAX inhibitors with the kinase activity engineered out
- A virtual screen flagged EGFR inhibitors, including dacomitinib and gefitinib-like cores, as possible BAX binders.
- Systematic modification built a first SAR for BAX inhibition and reduced EGFR kinase activity considerably.
- The series showed better BAX inhibition in vitro, in cells and in iPSC-derived brain organoids, with drug-like properties.
Inhibiting an executioner protein like BAX is hard, so starting from a privileged kinase scaffold is pragmatic. The real test is whether the EGFR activity is gone enough: a cytoprotectant that still hits kinases is a poor neuroprotective. I'd like orthogonal proof of direct BAX engagement and a broader kinome panel.
GTA182: a brain-penetrant MTA-cooperative PRMT5 inhibitor for MTAP-deleted tumors
- Structure-based design and multiparameter optimization gave GTA182, a tricyclic amide with strong selectivity for MTAP-deleted over wild-type cells.
- Low efflux and tuned physicochemical properties delivered unbound brain exposure in the efficacious range.
- Orally dosed, it caused regression in MTAP-deleted xenografts and an orthotopic glioblastoma model, and early Phase I data reported good tolerability and intracranial tumor shrinkage.
MTA-cooperative PRMT5 inhibitors are crowded, and brain exposure is the clear differentiator: MTAP deletion is common in glioblastoma, where most competitors can't reach the tumor. A clinical readout appearing in a medicinal chemistry paper is rare. I'd now look at hematologic safety, the usual liability for this class, and at how much of the intracranial effect is truly unbound-drug driven.
HTS framework finds small molecules that block tau binding to the LRP1 receptor
- The team built a quantitative assay set around purified LRP1 ligand-binding domain 4, using fluorescence polarization, split luciferase and TR-FRET.
- Tau, RAP and a peptide ligand competed for overlapping binding sites with nanomolar-range affinities across formats.
- A screen on this platform identified small-molecule inhibitors of the interaction, a starting point against tau uptake and spread.
Protein–protein interactions with a receptor ectodomain are tough targets, so three orthogonal assays is the right way to weed out artifacts. I'd treat the hits cautiously until they show activity in cellular tau-uptake assays and clear LRP1's many other ligands, such as ApoE and RAP, without broad liabilities.
High-Throughput Screening Identifies Small-Molecule Inhibitors of the Tau-LRP1 Interaction ↗
Cinchona-derived ammonium salts give long-lasting, sensory-selective nerve block
- Ammonium salts built on natural cinchona alkaloids were explored as local anesthetics; the bicyclic quincoridine skeleton beat acyclic and monocyclic analogues.
- Lead CLA-1-3 blocked the rat sciatic nerve for more than 50 hours and potently inhibited voltage-gated sodium channels.
- A second compound, CLA-3-5, gave a sensory-selective block lasting up to about 3 hours at 0.30–0.60% concentration.
Duration is the headline, but the permanently charged ammonium is the more interesting design choice: it should slow washout from the injection site, which probably explains the long action. For anything that lasts over 50 hours, though, I'd look at local neurotoxicity and myotoxicity data before the efficacy curves.
Cinchona Alkaloids-Derived Ammonium Salts for Long-Acting and Sensory-Selective Nerve Blockades ↗
Bicyclic amine swap widens the G2019S window in indazole LRRK2 inhibitors
- Structure-guided hybridization produced an indazole-based LRRK2 series; the initial piperidine compounds were potent but barely distinguished wild-type from G2019S mutant kinase.
- Replacing the piperidine with an octahydrocyclopenta[c]pyrrole widened the selectivity window while keeping good potency; compound 34 represents the new chemotype.
- The authors pitch it as an alternative starting point for next-generation, Parkinson's-directed LRRK2 inhibitors.
Locking a floppy piperidine into a fused bicycle is the textbook way to sharpen selectivity, and it seems to have paid off here. Before getting attached I'd check what the extra carbon framework costs in lipophilicity and brain exposure, because a CNS target punishes both. Mutant-over-wild-type selectivity also needs to hold up in cells, not just in biochemical assays.
Patient advocates press safety concerns over Neurocrine's Prader-Willi drug Vykat XR
- STAT reports growing alarm among patient advocates and some experts over the perceived risks of Neurocrine's rare disease drug Vykat XR (diazoxide choline) for Prader-Willi syndrome.
- Earlier coverage links the concern to fluid retention, respiratory and cardiac events in post-marketing reports, though causality has not been established.
- Neurocrine has said it keeps a favourable benefit-risk view and is working with the FDA and patient groups.
This is a launch-curve story. Neurocrine paid heavily for Vykat XR as a blockbuster hopeful, and prescriber caution in a small, fragile patient population can slow uptake long before any regulatory action. The key variables are whether the label changes and whether the planned 2027 study in higher-risk patients reassures.
STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug ↗
Donepezil-derived dual BuChE/FAAH inhibitors for multi-target Alzheimer's therapy
- Donepezil-based derivatives were designed and made as dual inhibitors of human butyrylcholinesterase and fatty acid amide hydrolase.
- Lead G15 inhibited both enzymes in a balanced way, with sub-micromolar to low-micromolar activity.
- It showed measurable selectivity over the carboxylesterases CES1 and CES2, a common liability for serine-hydrolase inhibitors.
Dual-target hybrids rarely land balanced potency on both enzymes, so G15 is a useful starting point. Selectivity over carboxylesterases is only modest, though, and I'd want in vivo exposure data before believing the multi-target rationale.
Hybrid indazole–bicyclic pyrrole chemotype targets mutant-selective LRRK2
- Structure-guided hybridization of an indazole with an octahydrocyclopenta[c]pyrrole gave a new LRRK2 inhibitor chemotype for Parkinson's disease.
- Early piperidine-containing analogs were potent but barely distinguished wild-type from G2019S LRRK2.
- Swapping the piperidine for the fused bicyclic amine was the change introduced to widen that selectivity window.
A narrow wild-type/G2019S window is the usual reason LRRK2 leads stall, so a scaffold change that buys mutant bias is worth a look. I'd want to see whether that bias holds in cells at physiological ATP and what the bicyclic amine does to brain penetration and clearance.
Viatris to buy Pacira for about $1.65B to add non-opioid pain franchise
- Viatris agreed to acquire Pacira BioSciences in an all-cash deal at $36.50 per share, a premium of roughly 45% to the last close.
- The prize is Pacira's non-opioid products EXPAREL for post-surgical pain and ZILRETTA for knee osteoarthritis pain, plus a knee OA gene therapy candidate.
- Closing is expected by the end of 2026, funded mainly from cash on hand.
This is Viatris buying a commercial pain franchise rather than science, which fits its pivot from generics toward branded cash flow. The pairing with its pending fast-acting meloxicam decision hints at a non-opioid pain sales force, though EXPAREL's generic-style competition is the long-term risk to watch.
Viatris to snap up Pacira's non-opioid pain pipeline for $1.65B ↗
Binding kinetics help isolate HDAC2-selective inhibitor KTT-1
- KTT-1 (compound 12) was identified as HDAC2-selective by evaluating both thermodynamics and kinetics of enzyme–inhibitor binding, rather than affinity alone.
- Crystallography of HDAC2 with the compound, plus quantum chemical calculations on model compounds, suggests its 2-furanyl group drives the selectivity.
- In cells it preferentially inhibited HDAC2 over the highly homologous HDAC1 and promoted neurite outgrowth; in stress-vulnerable mice it improved memory and depression-like behavior.
Screening on residence time rather than IC50 alone is how you get past the near-identical HDAC1/2 active sites, and a furanyl contact backed by both crystallography and QM is a clean, testable rationale. Cellular HDAC2-over-HDAC1 preference is rare, so I'd want it confirmed in neurons with real brain exposure.
DEL hit becomes brain-penetrant reversible MAGL inhibitor MAGLi 432
- A bicyclopiperazine hit from a DNA-encoded library was optimized by structure-guided design into compound 1.5 (MAGLi 432), a reversible MAGL inhibitor.
- The compound combines high potency, selectivity over other serine hydrolases and CNS drug-like properties, with a favorable oral half-life in rats.
- It inhibited MAGL in human brain homogenate and worked in mouse neuroinflammation models; the campaign was steered by a translational "Five-Star Matrix" framework.
Reversibility is the part I'd want here, since irreversible MAGL agents ran into CB1 desensitization on chronic dosing. A non-covalent DEL chemotype that already shows target engagement in human brain tissue is a good template, and I'd steal the habit of testing in human tissue early rather than at the end.
Tuned lanosterol derivative crosses the BBB and curbs Aβ burden in AD mice
- Lanosterol inhibits protein aggregation but has poor physicochemical and PK properties, so the authors tuned the hydrophilic–lipophilic balance around the 3-hydroxyl and the aliphatic side chain.
- Systematic screening gave compound 10, with markedly better metabolic stability and drug-like properties.
- Oral dosing of 10 rescued memory deficits and reduced Aβ burden in an Alzheimer's mouse model.
Natural-product sterols rarely survive their first PK table, so getting oral CNS exposure by tuning polarity around the 3-OH and side chain is the part I'd borrow. The open question is mechanism: efficacy in one mouse model is easy to over-read, and I'd want target engagement and sterol-pathway off-target data before getting excited.
Genentech pays Alector $100M upfront for brain-penetrant GCase therapy AL050
- Alector licensed AL050, a preclinical brain-penetrant engineered GCase enzyme replacement therapy for Parkinson's disease, to Genentech.
- The deal brings $100M upfront, up to $1.17B in milestones and tiered royalties; Genentech takes development, manufacturing and commercialization.
- Alector keeps its Brain Carrier platform, and the cash extends its runway into 2029.
A $100M upfront for a preclinical asset shows how much Roche values a validated blood-brain barrier shuttle in GBA1-linked Parkinson's. For Alector, it's a lifeline that funds its Alzheimer's and siRNA programs. The risk is that delivery, not the enzyme, is the real bet, and Genentech has other shuttle options.
Genentech pays Alector $100M for preclinical Parkinson's prospect ↗
OGG1 'organocatalytic switches' reprogram DNA repair to protect mitochondria
- Most OGG1 work has aimed at inhibitors; these mitochondria-enriched ORCAs instead reprogram the enzyme's catalysis.
- Biochemistry, mutagenesis and X-ray crystallography showed active-site binding that favors beta-elimination over glycosylase turnover.
- ORCAs protected mitochondrial function under oxidative stress, raised NAD levels in cortical neurons and were neuroprotective in a retina axotomy model.
Activating rather than inhibiting an enzyme is rare and hard to do, so a crystal structure showing the mechanism is what makes this credible. The open question is long-term safety: pushing a repair enzyme to a different catalytic outcome could create unusual DNA lesions, and the neuroprotection data are still early.
Development of Organocatalytic Switches of OGG1 that Protect Mitochondria under Oxidative Stress ↗
A Quinazoline Nav1.7 Lead, Absolute Configuration Fixed by MicroED, Shows Oral Analgesia in Rodents
- Starting from a modest focused-library quinazoline hit, SAR across about twenty analogs gave a chiral lead with sub-micromolar potency and clear selectivity over Nav1.5.
- The absolute configuration was assigned by MicroED, so the active enantiomer is unambiguous without large crystals.
- The lead had acceptable oral exposure, reduced pain behavior in two rodent models, and was clean in a 44-target off-panel; Nav1.7-knockout neuron controls support on-target action.
Nav1.7 has burned a lot of programs on selectivity and translation, so a clean off-target panel plus knockout-neuron controls is what I'd look at first. Potency is still modest and the dose needed is high, so this is a starting scaffold rather than a candidate. The practical takeaway is MicroED: assigning chirality from nanocrystals of an early lead saves weeks of enantiomer chasing.
BmTACs Ride Age-Upregulated Transcytosis to Deliver a ROS-Activated DAPK1 Degrader into the Brain
- Brain delivery is the main barrier for degraders in neurodegeneration; BmTACs attach a macrocyclic peptide shuttle that exploits caveolae-mediated transcytosis, which rises with age in brain endothelium.
- A reactive-oxygen-species-responsive cage on the VHL ligand keeps the PROTAC inactive until it reaches high-ROS tissue.
- The platform is designed to remove activated DAPK1 selectively in the aging brain.
Two gating layers, shuttle for entry and ROS cage for activation, is clever systems design, but it moves the problem from medicinal chemistry to conjugate CMC and PK. I'd look hard at the unmasked-PROTAC fraction in periphery and at the shuttle's dependence on aged-endothelium biology, which could narrow the patient window. A real step for CNS degraders if the in vivo data hold up.
AbbVie's Tavapadon (Juvmo) Pill Wins FDA Approval for Parkinson's Disease
- FDA approved AbbVie's Juvmo (tavapadon), a once-daily oral pill for Parkinson's disease, usable alone early on or alongside levodopa for motor fluctuations.
- It's the first selective D1/D5 dopamine receptor partial agonist approved for Parkinson's, a mechanism distinct from older D2/D3 agonists, aimed at controlling motor symptoms with fewer impulse-control or sleep-attack risks.
- AbbVie gained tavapadon via its 2023 Cerevel Therapeutics acquisition; US launch is planned October 2026.
This is AbbVie's first tangible payoff from the $8.7B Cerevel bet — proof the deal wasn't just pipeline padding. But novelty alone won't move share: Parkinson's prescribing is sticky, generics dominate, and neurologists switch stable patients reluctantly. The cleaner side-effect profile is a real wedge, yet formulary inertia will decide if it's more than a niche add-on.
Neutral, CSF-Penetrant TTR Stabilizers Designed with Heterocyclic Linkers
- A new series of neutral, heterocyclic-linker-containing transthyretin (TTR) stabilizers is designed for improved brain and cerebrospinal fluid (CSF) penetration.
- Aims to address CNS/leptomeningeal manifestations of hereditary ATTR amyloidosis, where existing acidic stabilizers such as tafamidis show limited CNS exposure.
- Heterocyclic linker modifications reduced compound acidity relative to earlier chemotypes while reportedly preserving TTR tetramer-stabilizing potency and selectivity in vitro.
Finally—someone attacking the acidic-pharmacophore/P-gp efflux tradeoff head-on instead of just tolerating tafamidis's CNS blind spot. Ditching the carboxylic acid for heterocyclic linkers while holding onto tetramer-stabilizing potency is the hard part of this SAR, not the easy part. If CSF exposure holds up in vivo, leptomeningeal ATTR patients finally get a real option instead of an afterthought.
Brain-Penetrant Covalent BChE Inhibitor Shows Procognitive Effects in Alzheimer's Model
- Researchers used structure-guided design to develop a covalent small-molecule inhibitor of human butyrylcholinesterase (BChE), an enzyme increasingly implicated in Alzheimer's disease progression.
- The lead compound was engineered for blood-brain barrier penetration, a key hurdle for centrally acting cholinesterase inhibitors.
- In vivo testing showed procognitive efficacy, supporting covalent BChE inhibition as a potential treatment approach for Alzheimer's disease.
BChE rising while AChE falls late in disease is finally moving the field past AChE-centric dogma. A covalent warhead in a serine hydrolase family full of close paralogs (AChE, esterases) needs hard selectivity data, not just potency. What actually differentiates this from rivastigmine-class reversible inhibitors is CNS penetration — brain exposure they never solved well.
Fragment Growing Explored to Improve a Natural Cysteine-Sulfoxide BACE-1 Inhibitor
- Alliin, a natural cysteine-sulfoxide that chelates BACE-1's catalytic dyad, has poor pharmacokinetics, limiting its use as a drug lead.
- Researchers used a fragment-growing strategy guided by molecular dynamics simulations to build out from this core, aiming to improve affinity and drug-like properties.
- The campaign remains an early-stage computational effort, not a validated clinical candidate.
Starting from a food-derived fragment like alliin is seductive — built-in tox clearance, cheap chirality — but BACE-1 is where good binders go to die clinically (verubecestat, lanabecestat, atabecestat all crashed on safety/efficacy despite clean biochemistry). Growing a fragment computationally is the easy 80%; without disclosed SPR/ITC or crystallography backing the MD poses, I'd treat the affinity gains as hypotheses, not results.
Alkermes' Sleep-Drug Class Shows Early Promise Against ADHD
- Alkermes reported positive Phase 1b data for ALKS 7290, an orexin 2 receptor agonist, showing a substantial reduction in ADHD symptom scores after two weeks at the high dose, with the drug generally well tolerated.
- Cognitive and EEG-based biomarker tests also showed improvements in processing speed, working memory, and sustained attention.
- A Phase 2 study is now enrolling, with data expected in 2027.
Orexin agonists have mostly been a narcolepsy story (Takeda, Axsome); Alkermes just repositioned the same mechanism as a wakefulness/cognition play for ADHD, a market still dominated by stimulants and Qelbree-style non-stimulants. The Phase 1b n is small and it's only two-week data, but the EEG biomarker improvements give it more credibility than a symptom-score readout alone would.
Alkermes' orexin agonist shows potential to treat ADHD in early-stage trial ↗
Telix Bets $1.65B on Radiopharma Rival to Take On Novartis
- Telix Pharmaceuticals agreed to acquire Germany's ITM for $1.65 billion upfront, plus up to $700 million in milestones tied to its lead radiopharmaceutical candidate.
- The deal pairs Telix's diagnostics business with ITM's lutetium-177 supply chain, setting up direct competition with Novartis' Lutathera in neuroendocrine cancer.
- Telix will assume some of ITM's debt, and the companies expect to close the transaction by year-end 2026.
At $1.65B upfront plus $700M in milestones — and assumed debt pushing the all-in cost near $2.4B — Telix is essentially replicating Novartis's own AAA/Endocyte playbook: buy the isotope supply chain, not just the molecule. Pairing ITM's Lu-177 manufacturing with Telix's diagnostics scale is the only realistic way a challenger dents Lutathera's neuroendocrine near-monopoly.
Telix beams into Novartis' territory with $1.6B ITM acquisition ↗
Tuning Brain Penetration in DYRK1A Inhibitors for Alzheimer's Neuroinflammation
- Builds on a prior azaindole-quinazoline lead compound and addresses its limited blood-brain barrier penetration.
- Uses an intramolecular cyclization strategy to mask a hydrogen-bond-donating amine group that was prone to P-glycoprotein-mediated efflux.
- Resulting analogs retain strong DYRK1A inhibitory activity while markedly improving brain exposure.
- Optimized compounds reduce microglia-driven neuroinflammatory markers in disease-relevant models.
Masking an H-bond donor by intramolecular cyclization to dodge P-gp is a well-worn CNS trick, but pulling it off on an azaindole-quinazoline kinase core without bleeding DYRK1A potency is the part most efflux-liability campaigns fail at. If the microglial neuroinflammation readout replicates in a second model, this is a genuinely reusable template for other P-gp-limited kinase programs.
Alkermes Reports First Positive Orexin-Agonist Data in ADHD With ALKS 7290 Phase 1b Trial
- Phase 1b study randomized 88 healthy volunteers and 50 adults with ADHD to ALKS 7290 20mg, 50mg, or placebo for 14 days, following a 2-week washout of existing ADHD medications.
- Participants began with a median AISRS score of ~39 (moderate-to-severe); by Day 14, reported median reductions were 14.0 points with 20mg and 19.0 points with 50mg, with the higher dose bringing scores into the mild range.
- Improvement was reported as early as Day 6 and spanned both inattentive and hyperactivity/impulsivity subscales; CGI-S scores fell by a median of 1 point (20mg) and 2 points (50mg).
- The drug was generally well tolerated across doses.
- This marks the first clinical evidence that an orexin 2 receptor agonist -- a drug class previously studied for rare sleep disorders like narcolepsy -- can improve ADHD symptoms.
- Alkermes describes the results as exploratory proof-of-concept rather than a powered efficacy readout, and says they support the dosing already chosen for an ongoing Phase 2 trial.
A genuinely new mechanism in ADHD is rare and commercially precious — this is the first clinical signal that orexin-2 agonism, a pathway built for narcolepsy, can move core ADHD symptoms, in a market still anchored by decades-old stimulant chemistry and underwhelming non-stimulants like atomoxetine and viloxazine. If it replicates, a non-stimulant with this magnitude of effect and no controlled-substance baggage would be a real wedge against stimulant-class incumbents. But read the fine print: only 50 ADHD patients, an unpowered Phase 1b that Alkermes itself calls exploratory proof-of-concept — sizeable AISRS drops here can evaporate once a properly powered, placebo-controlled Phase 2 reads out. For Alkermes, it's a second shot on goal for the orexin-2 franchise beyond narcolepsy (ALKS 2680), spreading platform risk into a much larger indication. Investors should treat this as a call option, not a catalyst, until Phase 2 data land.
Alkermes' orexin agonist shows potential to treat ADHD in early-stage trial ↗
New Benzimidazole-Tetrahydrofuran Series Delivers Potent, Selective NaV1.8 Inhibitor Lead for Pain
- NaV1.8 inhibition is a clinically validated non-opioid strategy for pain, with the marketed drug VX-548 (Journavx) serving as the benchmark; its metabolic pathways in humans and rats are well characterized.
- Researchers designed a new chemotype, 2-(2-benzimidazole)-substituted tetrahydrofurans, and applied structure-based optimization to circumvent VX-548's known metabolic liabilities while retaining nanomolar NaV1.8 potency and subtype selectivity.
- The resulting lead, compound 31, showed favorable oral bioavailability in rats, with plasma AUC more than 10-fold higher than VX-548, alongside potent in vivo analgesic efficacy.
- Pharmacokinetic behavior was consistent across species, with favorable profiles also seen in beagle dogs and cynomolgus monkeys.
- Compound 31 exhibited a favorable early safety profile, including no genotoxicity and weak hERG inhibition, supporting its status as a metabolically optimized preclinical lead for further evaluation.
Call this a metabolism play more than a new-target story. With VX-548's clearance liabilities already mapped in human and rat, swapping to a 2-benzimidazole-tetrahydrofuran scaffold reads as targeted scaffold-hopping around known soft spots rather than blind SAR exploration. That's the efficient way to run a fast-follower program: let the first approved drug's ADME data write your design brief. A >10x jump in rat AUC is the number that matters here — that's the difference between a compound needing frequent dosing with exposure gaps and one you can actually push into efficacy studies with margin. Clean hERG and no genotox flags this early derisks the biggest attrition risks before you've spent tox budget. The THF-benzimidazole core isn't exotic chemistry, nothing hard to scale — this looks like a real backup/second-gen candidate, not just a paper compound.
Novartis Discontinues ALS Program After Lifonebart Misses Phase 2 Endpoints
- Novartis has discontinued development of lifonebart (VHB937), a TREM2 stabilizer/activator antibody, in amyotrophic lateral sclerosis (ALS).
- The decision follows Phase 2 ASTRALS trial results in which the drug missed both its primary and secondary endpoints.
- The study enrolled 251 patients with early-stage ALS; the primary endpoint was a composite of ventilator-free survival and change on the ALS Functional Rating Scale-Revised (ALSFRS-R), assessed at 40 weeks.
- The ALS discontinuation marks roughly the fourth pipeline setback for Novartis within about a month, part of a broader run of recent clinical disappointments.
- Lifonebart is not being abandoned entirely: Novartis continues to evaluate VHB937 in a separate, ongoing Phase 2 trial in early Alzheimer's disease.
Four pipeline setbacks in a month is a signal on Novartis's neuroscience screening bar, not just one bad trial. Either the Phase 2 go/no-go criteria were too generous or the underlying biology cases were weaker than the licensing rationale implied. On TREM2: one ALS miss doesn't kill the mechanism class — microglial-activation targets have had mixed reads across sponsors — but it does narrow the story to indication selection. The real tell is that Novartis kept the Alzheimer's Phase 2 running; that's management's actual vote on whether TREM2 biology holds, and it's the readout that will move the thesis. Watch for further neuro pruning next quarter, Alzheimer's data timing, and whether other TREM2-chasing biotech partners re-rate the target class.
Novartis ends ALS program after phase 2 flop, adding to R&D woes ↗